HTG Molecular Diagnostics Valuation Multiples

Discover revenue and EBITDA valuation multiples for HTG Molecular Diagnostics and similar public comparables like Strata Skin Sciences, Lipella Pharmaceuticals, ViewRay, Acutus Medical and more.

HTG Molecular Diagnostics Overview

About HTG Molecular Diagnostics

HTG Molecular Diagnostics Inc is a life science company whose mission is to advance precision medicine through its transcriptome-wide profiling and medicinal chemistry technologies. The company derives revenue from sales of its HTG EdgeSeq system and integrated next-generation sequencing-based HTG EdgeSeq research use only assays and from sample processing services performed in its VERI/O laboratory. The company operates in one segment and its customers and distributors are located in the United States and Europe.


Founded

1997

HQ

United States

Employees

54

Financials (FY)

Revenue: $6M
EBITDA: ($20M)

Market Cap

$0K

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

HTG Molecular Diagnostics Financials

HTG Molecular Diagnostics reported last fiscal year revenue of $6M and negative EBITDA of ($20M).

In the same fiscal year, HTG Molecular Diagnostics generated $2M in gross profit, ($20M) in EBITDA losses, and had net loss of ($22M).


HTG Molecular Diagnostics P&L

In the most recent fiscal year, HTG Molecular Diagnostics reported revenue of $6M and EBITDA of ($20M).

HTG Molecular Diagnostics is unprofitable as of last fiscal year, with gross margin of 28%, EBITDA margin of (316%), and net margin of (339%).

See analyst estimates for HTG Molecular Diagnostics
Last FY202620272028
Revenue$6M
Gross Profit$2M
Gross Margin28%
EBITDA($20M)
EBITDA Margin(316%)
EBIT Margin(327%)
Net Profit($22M)
Net Margin(339%)

Financial data powered by Morningstar, Inc.

HTG Molecular Diagnostics Stock Performance

HTG Molecular Diagnostics has current market cap of $0K.

Market CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$0K-----

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

HTG Molecular Diagnostics Valuation Multiples

HTG Molecular Diagnostics trades at (0.4x) EV/Revenue multiple, and 0.1x EV/EBITDA.

See NTM and 2027E valuation multiples for HTG Molecular Diagnostics

HTG Molecular Diagnostics Financial Valuation Multiples

As of August 14, 2026, HTG Molecular Diagnostics has market cap of $0K.

HTG Molecular Diagnostics has a P/E ratio of 0.0x.

Last FY202620272028
EV/Revenue(0.4x)
EV/EBITDA0.1x
EV/EBIT0.1x
EV/Gross Profit(1.4x)
P/E0.0x
EV/FCF0.1x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified HTG Molecular Diagnostics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

HTG Molecular Diagnostics Margins & Growth Rates

In the most recent fiscal year, HTG Molecular Diagnostics reported gross margin of 28%, EBITDA margin of (316%), and net margin of (339%).

See estimated margins and future growth rates for HTG Molecular Diagnostics

HTG Molecular Diagnostics Margins

Last FY202720282029
Gross Margin28%
EBITDA Margin(316%)
EBIT Margin(327%)
Net Margin(339%)
FCF Margin(290%)

Data powered by FactSet, Inc. and Morningstar, Inc.

HTG Molecular Diagnostics Operational KPIs

HTG Molecular Diagnostics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Access forward-looking KPIs for HTG Molecular Diagnostics
Last FY202620272028
Revenue per Employee$0.1M
Opex per Employee$0.4M
R&D Expenses to Revenue107%
Opex to Revenue355%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

HTG Molecular Diagnostics Competitors

HTG Molecular Diagnostics competitors include Strata Skin Sciences, Lipella Pharmaceuticals, ViewRay, Acutus Medical, Viveve Medical, Evome Medical, Remedent and Easton Pharmaceuticals.

Most HTG Molecular Diagnostics public comparables operate across Life Sciences Tools, Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Strata Skin Sciences0.3x-47.2x-
Lipella Pharmaceuticals(3.0x)-0.3x-
ViewRay0.0x-(0.0x)-
Acutus Medical1.1x-9.7x-
Viveve Medical0.0x-(0.0x)-
Evome Medical0.3x-(1.9x)-

This data is available for Pro users. Sign up to see all HTG Molecular Diagnostics competitors and their valuation data.

Start Free Trial

HTG Molecular Diagnostics VC Funding History

Before going public, HTG Molecular Diagnostics raised $8M in total equity funding, across 1 round.


HTG Molecular Diagnostics Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Feb-14Series E-$8M-HTG Molecular Diagnostics is a molecular diagnostics company that develops NGS-based profiling technology for precision medicine applications. The company's proprietary HTG EdgeSeq technology performs complex, highly multiplexed molecular profiling from solid and liquid samples. The company eventually completed an initial public offering in May 2015, raising $50 million by offering 3.6 million shares at $14 per share on the Nasdaq under ticker HTGM. By year-end 2015, HTG had generated $4 million in revenue, including $3.5 million from product sales.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About HTG Molecular Diagnostics

When was HTG Molecular Diagnostics founded?HTG Molecular Diagnostics was founded in 1997.
Where is HTG Molecular Diagnostics headquartered?HTG Molecular Diagnostics is headquartered in United States.
How many employees does HTG Molecular Diagnostics have?As of today, HTG Molecular Diagnostics has over 54 employees.
Is HTG Molecular Diagnostics publicly listed?Yes, HTG Molecular Diagnostics is a public company listed on OTCM.
What is the stock symbol of HTG Molecular Diagnostics?HTG Molecular Diagnostics trades under HTGMQ ticker.
When did HTG Molecular Diagnostics go public?HTG Molecular Diagnostics went public in 2015.
Who are competitors of HTG Molecular Diagnostics?HTG Molecular Diagnostics main competitors include Strata Skin Sciences, Lipella Pharmaceuticals, ViewRay, Acutus Medical, Viveve Medical, Evome Medical, Remedent, Easton Pharmaceuticals.
What is the current market cap of HTG Molecular Diagnostics?HTG Molecular Diagnostics' current market cap is $0K.
What is the current revenue of HTG Molecular Diagnostics?HTG Molecular Diagnostics' last fiscal year revenue is $6M.
What is the current EV/Revenue multiple of HTG Molecular Diagnostics?Current revenue multiple of HTG Molecular Diagnostics is (0.4x).
Is HTG Molecular Diagnostics profitable?No, HTG Molecular Diagnostics is not profitable.
How many companies HTG Molecular Diagnostics has acquired to date?HTG Molecular Diagnostics hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies HTG Molecular Diagnostics has invested to date?HTG Molecular Diagnostics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to HTG Molecular Diagnostics

Lists including HTG Molecular Diagnostics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial